[The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
Griebenow
R
R
Städtische Kliniken Merheim, Köln. zinsikc@kliniken-koeln.de
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D003327:Coronary Disease / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D015337:Multicenter Studies as Topic; D011758:Pyrroles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control*; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin